{"protocolSection": {"identificationModule": {"nctId": "NCT02528214", "orgStudyIdInfo": {"id": "EFC13691"}, "secondaryIdInfos": [{"id": "2015-001573-40", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1170-7152", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma", "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma", "acronym": "VENTURE"}, "statusModule": {"statusVerifiedDate": "2017-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-10-15"}, "primaryCompletionDateStruct": {"date": "2017-09-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-11-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-08-18", "studyFirstSubmitQcDate": "2015-08-18", "studyFirstPostDateStruct": {"date": "2015-08-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-07-27", "resultsFirstSubmitQcDate": "2018-10-19", "resultsFirstPostDateStruct": {"date": "2018-10-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-09-18", "lastUpdatePostDateStruct": {"date": "2019-10-01", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}, "collaborators": [{"name": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Primary Objective:\n\nTo evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma.\n\nSecondary Objectives:\n\n* To evaluate the safety and tolerability of dupilumab.\n* To evaluate the effect of dupilumab in improving participants-reported outcomes.\n* To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.", "detailedDescription": "The total study duration per participant was up to 46 weeks, consisting of a screening period of 3 to up to 8 weeks (up to 10 weeks for participants who experienced a clinically significant asthma exacerbation during the screening period), a randomized treatment period of up to 24 weeks, and a post-treatment period of 12 weeks.\n\nParticipants who completed treatment were considered for eligibility into the long term extension study LTS12551 (NCT02134028)."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 210, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo q2w", "type": "PLACEBO_COMPARATOR", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Placebo", "Drug: Oral corticosteroid therapy (prednisone/prednisolone)", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}, {"label": "Dupilumab 300 mg q2w", "type": "EXPERIMENTAL", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Dupilumab", "Drug: Oral corticosteroid therapy (prednisone/prednisolone)", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}], "interventions": [{"type": "DRUG", "name": "Dupilumab", "description": "Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.", "armGroupLabels": ["Dupilumab 300 mg q2w"], "otherNames": ["REGN668", "SAR231893"]}, {"type": "DRUG", "name": "Placebo", "description": "Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.", "armGroupLabels": ["Placebo q2w"]}, {"type": "DRUG", "name": "Oral corticosteroid therapy (prednisone/prednisolone)", "description": "Oral administration.", "armGroupLabels": ["Dupilumab 300 mg q2w", "Placebo q2w"]}, {"type": "DRUG", "name": "Inhaled corticosteroid (ICS) therapy", "description": "Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).", "armGroupLabels": ["Dupilumab 300 mg q2w", "Placebo q2w"]}, {"type": "DRUG", "name": "Albuterol/Salbutamol", "description": "Oral inhalation as needed.", "armGroupLabels": ["Dupilumab 300 mg q2w", "Placebo q2w"]}, {"type": "DRUG", "name": "Levalbuterol/Levosalbutamol", "description": "Oral inhalation as needed.", "armGroupLabels": ["Dupilumab 300 mg q2w", "Placebo q2w"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control", "description": "Percentage reduction of OCS dose was calculated as (optimized OCS dose \\[mg/day\\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.", "timeFrame": "Baseline, Week 24"}, {"measure": "Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \\[mg/day\\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the reduction of OCS dose to \\<5 mg/day was achieved at Week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control", "description": "For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.", "timeFrame": "Week 24"}, {"measure": "Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Absolute reduction was calculated by subtracting Week 24 value from baseline value.", "timeFrame": "Baseline and Week 24"}], "otherOutcomes": [{"measure": "Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period", "description": "A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \\>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 24"}, {"measure": "Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12 and Week 24"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24", "description": "The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "timeFrame": "Baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24", "description": "AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "timeFrame": "Baseline, Week 12 and Week 24"}, {"measure": "Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24", "description": "EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).", "timeFrame": "Baseline, Week 12 and Week 24"}, {"measure": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24", "description": "The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.", "timeFrame": "Baseline, Week 12 and Week 24"}, {"measure": "Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24", "description": "The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.", "timeFrame": "Baseline, Week 12 and Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria :\n\nAdult and adolescent (12 years of age or older) participants with a physician diagnosis of asthma for \\>=12 months, based on the Global Initiative for Asthma (GINA) 2014 guidelines and the following criteria:\n\n* Participants with severe asthma and a well-documented, regular prescribed treatment of maintenance corticosteroids in the 6 months prior to Visit 1 and using a stable OCS dose (ie, no change of OCS dose) for 4 weeks prior to Visit 1. Participants must be taking 5 to 35 mg/day of prednisone/prednisolone, or the equivalent, at Visit 1 and at the randomization visit. In addition, the participants must agree to switch to study-required prednisone/prednisolone as their OCS and use it per protocol for the duration of the study.\n* Existing treatment with high-dose inhaled corticosteroid (ICS; \\>500 mcg total daily dose of fluticasone propionate or equivalent) in combination with a second controller (ie, long-acting beta agonist \\[LABA\\], leukotriene receptor antagonist \\[LTRA\\]) for at least 3 months with a stable dose of ICS for \\>=1 month prior to Visit 1. In addition, participants requiring a third controller for their asthma are considered eligible for this study, and it should also be used for at least 3 months with a stable dose \\>= 1 month prior to Visit 1.\n* A forced expiratory volume in 1 second (FEV1) \\<80% of predicted normal for adults and \\<=90% of predicted normal for adolescents at Visit 1.\n* Evidence of asthma as documented by either: reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 mcg (2 to 4 inhalations of albuterol/salbutamol or levalbuterol/levosalbutamol, or of a nebulized solution of albuterol/salbutamol or levalbuterol/levosalbutamol, if considered as a standard office practice) before randomization or documented in the 12 months prior to Visit 1 OR airway hyperresponsiveness (methacholine: provocative concentration that causes a positive reaction \\[PC20\\] of \\<8 mg/mL) documented in the 12 months prior to Visit 1.\n\nExclusion criteria:\n\n* Participants \\<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who were \\>=18 years of age).\n* Participants who weighed \\<30.0 kg.\n* Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, allergic bronchopulmonary aspergillosis, cystic fibrosis) which may impair lung function.\n* Clinical evidence or imaging (eg, chest X-ray, computed tomography, magnetic resonance imaging) within 12 months of Visit 1 with clinically significant findings of lung disease(s) other than asthma, as per local standard of care.\n* A participant who experiences a deterioration of asthma that results in emergency treatment or hospitalization within 4 weeks of Screening Visit 1.\n* A participant who requires 12 puffs or more of rescue medication on any 1 day in the week prior to Visit 1.\n* A participant who has experienced an upper or lower respiratory tract infection within the 4 weeks prior to screening.\n* Current smoker or cessation of smoking within 6 months prior to Visit 1.\n* Previous smoker with a smoking history \\>10 pack-years.\n* Comorbid disease that might interfere with the evaluation of the investigational medicinal product.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number 840022", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840014", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Investigational Site Number 840002", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840010", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840062", "city": "Amarillo", "state": "Texas", "zip": "79106", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Investigational Site Number 840070", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Investigational Site Number 840128", "city": "McKinney", "state": "Texas", "zip": "75071", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Investigational Site Number 840118", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Investigational Site Number 032003", "city": "Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032001", "city": "Caba", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032091", "city": "Caba", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 056002", "city": "Brussels", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Investigational Site Number 056003", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "Investigational Site Number 056001", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Investigational Site Number 076011", "city": "Sao Paulo", "zip": "04020-041", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 076002", "city": "Sorocaba", "zip": "18040-425", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Investigational Site Number 076013", "city": "S\u00e3o Bernardo Do Campo", "zip": "09780-000", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "Investigational Site Number 124009", "city": "Calgary", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Investigational Site Number 124016", "city": "Hamilton", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Investigational Site Number 124003", "city": "Mississauga", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Investigational Site Number 124013", "city": "Ottawa", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Investigational Site Number 124002", "city": "Toronto", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124017", "city": "Vancouver", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number 152007", "city": "Quillota", "zip": "2260877", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Investigational Site Number 152005", "city": "Santiago", "zip": "7500692", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152008", "city": "Talca", "zip": "3460001", "country": "Chile", "geoPoint": {"lat": -35.4264, "lon": -71.65542}}, {"facility": "Investigational Site Number 170001", "city": "Bogota", "zip": "110121", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 170006", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 348301", "city": "Balassagyarmat", "zip": "2660", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Investigational Site Number 348303", "city": "Edel\u00e9ny", "zip": "3780", "country": "Hungary", "geoPoint": {"lat": 48.3, "lon": 20.73333}}, {"facility": "Investigational Site Number 376003", "city": "Haifa", "zip": "34362", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Investigational Site Number 376001", "city": "Kfar Saba", "zip": "44281", "country": "Israel", "geoPoint": {"lat": 32.175, "lon": 34.90694}}, {"facility": "Investigational Site Number 376005", "city": "Petah-Tikva", "zip": "49100", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Investigational Site Number 376002", "city": "Rehovot", "zip": "76100", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Investigational Site Number 376004", "city": "Tel Hashomer", "zip": "52621", "country": "Israel", "geoPoint": {"lat": 32.04195, "lon": 34.85623}}, {"facility": "Investigational Site Number 380005", "city": "Catania", "zip": "95123", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Investigational Site Number 380002", "city": "Genova", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Investigational Site Number 380008", "city": "Napoli", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "Investigational Site Number 380009", "city": "Palermo", "zip": "90146", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Investigational Site Number 380001", "city": "Pisa", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Investigational Site Number 380003", "city": "Reggio Emilia", "zip": "42123", "country": "Italy", "geoPoint": {"lat": 44.69825, "lon": 10.63125}}, {"facility": "Investigational Site Number 484016", "city": "Acapulco", "zip": "39670", "country": "Mexico", "geoPoint": {"lat": 16.86336, "lon": -99.8901}}, {"facility": "Investigational Site Number 484013", "city": "Chihuahua", "zip": "31020", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Investigational Site Number 484001", "city": "Guadalajara", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484002", "city": "Mexico, Df", "zip": "06726", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigational Site Number 484003", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 528001", "city": "Arnhem", "zip": "6815 AD", "country": "Netherlands", "geoPoint": {"lat": 51.98, "lon": 5.91111}}, {"facility": "Investigational Site Number 528002", "city": "Dordrecht", "zip": "3318 AT", "country": "Netherlands", "geoPoint": {"lat": 51.81, "lon": 4.67361}}, {"facility": "Investigational Site Number 616006", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Investigational Site Number 616097", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616001", "city": "Lodz", "zip": "90-141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616010", "city": "Warszawa", "zip": "04-141", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Investigational Site Number 616011", "city": "Znin", "zip": "88-400", "country": "Poland", "geoPoint": {"lat": 52.84958, "lon": 17.71992}}, {"facility": "Investigational Site Number 642104", "city": "Bucharest", "zip": "011461", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigational Site Number 642103", "city": "Bucharest", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Investigational Site Number 642102", "city": "Cluj-Napoca", "zip": "400162", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642107", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642108", "city": "Cluj-Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Investigational Site Number 642105", "city": "Timisoara", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 642106", "city": "Timisoara", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Investigational Site Number 643006", "city": "Moscow", "zip": "105077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643007", "city": "Moscow", "zip": "117574", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643011", "city": "Saint-Petersburg", "zip": "194356", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643099", "city": "St-Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643009", "city": "St-Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 724014", "city": "Barcelona", "zip": "08023", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724002", "city": "Barcelona", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724013", "city": "Madrid", "zip": "28942", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Investigational Site Number 724006", "city": "Pozuelo De Alarc\u00f3n", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Investigational Site Number 724007", "city": "Sant Boi De Llobregat", "zip": "08830", "country": "Spain", "geoPoint": {"lat": 41.34357, "lon": 2.03659}}, {"facility": "Investigational Site Number 724096", "city": "Santiago De Compostela", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Investigational Site Number 804007", "city": "Chernivtsi", "zip": "58001", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Investigational Site Number 804004", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804009", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804001", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804003", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804011", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804006", "city": "Odessa", "zip": "65025", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Investigational Site Number 804002", "city": "Poltava", "zip": "36038", "country": "Ukraine", "geoPoint": {"lat": 49.59373, "lon": 34.54073}}, {"facility": "Investigational Site Number 804019", "city": "Vinnytsya", "zip": "21001", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}, "referencesModule": {"references": [{"pmid": "29782224", "type": "RESULT", "citation": "Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21."}, {"pmid": "35809937", "type": "DERIVED", "citation": "Lugogo N, Mohan A. Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics? Chest. 2022 Jul;162(1):4-5. doi: 10.1016/j.chest.2022.04.004. No abstract available."}, {"pmid": "35636689", "type": "DERIVED", "citation": "Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28."}, {"pmid": "35398549", "type": "DERIVED", "citation": "Domingo C, Maspero JF, Castro M, Hanania NA, Ford LB, Halpin DMG, Jackson DJ, Daizadeh N, Djandji M, Mitchell CP, Crikelair N, Jacob-Nara JA, Deniz Y, Rowe PJ, Ortiz B. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1835-1843. doi: 10.1016/j.jaip.2022.03.020. Epub 2022 Apr 8."}, {"pmid": "35217003", "type": "DERIVED", "citation": "Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22."}, {"pmid": "34752208", "type": "DERIVED", "citation": "Tohda Y, Matsumoto H, Miyata M, Taguchi Y, Ueyama M, Joulain F, Arakawa I. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2022 Nov;59(11):2162-2173. doi: 10.1080/02770903.2021.1996596. Epub 2021 Dec 8."}], "seeAlsoLinks": [{"label": "Related Info", "url": "https://www.ncbi.nlm.nih.gov/pubmed/?term=29782224&report=abstract"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Screening period included an OCS optimization phase (up to 10 weeks) where participants using OCS other than prednisone/prednisolone switched to these OCS. At the end of period, participants were randomized in 1:1 ratio (dupilumab:placebo).Randomization was stratified by optimized OCS dose (=\\<10 \\& \\>10 mg/day) at randomization visit \\& by country.", "recruitmentDetails": "The study was conducted at 68 centers in 17 countries. A total of 390 participants were screened between October 2015 \\& April 2017, of which,210 were randomized \\& treated. 180 participants were screen failures mainly due to exclusion criteria met \\& inclusion criteria not met. Assignment was done by Interactive Voice/Web Response System(IVRS/IWRS).", "groups": [{"id": "FG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "FG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "107"}, {"groupId": "FG001", "numSubjects": "103"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "107"}, {"groupId": "FG001", "numSubjects": "103"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "107"}, {"groupId": "FG001", "numSubjects": "100"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Other than specified above", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Baseline population included all randomized participants.", "groups": [{"id": "BG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "BG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "103"}, {"groupId": "BG002", "value": "210"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.7", "spread": "12.8"}, {"groupId": "BG001", "value": "51.9", "spread": "12.5"}, {"groupId": "BG002", "value": "51.3", "spread": "12.6"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "<18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Between 18 and 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "179"}]}]}, {"title": ">=65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "28"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "127"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "83"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "45"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "165"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian/White", "categories": [{"measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "197"}]}]}, {"title": "Black/of African descent", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Asian/Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Baseline Blood Eosinophil Count", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<0.15 Giga/L", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "60"}]}, {"title": ">=0.15 - <0.3 Giga/L", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "61"}]}, {"title": ">=0.3 Giga/L", "measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "89"}]}]}]}, {"title": "Baseline Optimized Daily OCS Dose", "description": "During screening period and before randomization, OCS dose was adjusted in each participant to achieve the lowest OCS dose, also known as optimized dose, required for management of participant's asthma.Participants using OCS medications other than prednisone/prednisolone were switched to either of these corticosteroids at a dose clinically comparable to their current stable OCS dose. To optimize the OCS dose, investigators were instructed to adjust the OCS dose weekly according to a pre-specified titration schedule, based on changes in participant's asthma control, and their clinical judgment.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.75", "spread": "6.31"}, {"groupId": "BG001", "value": "10.75", "spread": "5.9"}, {"groupId": "BG002", "value": "11.26", "spread": "6.12"}]}]}]}, {"title": "Daily OCS Dose at Visit 1 (i.e. preoptimization)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.83", "spread": "6.02"}, {"groupId": "BG001", "value": "11.79", "spread": "6.4"}, {"groupId": "BG002", "value": "11.81", "spread": "6.20"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control", "description": "Percentage reduction of OCS dose was calculated as (optimized OCS dose \\[mg/day\\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.", "populationDescription": "Analysis was performed on intent-to-treat (ITT) population which included randomized population analysed according to the treatment group allocated by randomization regardless of whether the treatment kit was used or not.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage reduction from baseline", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.85", "spread": "4.57"}, {"groupId": "OG001", "value": "70.09", "spread": "4.90"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The outcome measure was analyzed using analysis of covariance (ANCOVA) model which included percentage reduction of OCS dose at Week 24 as the response variable, and treatment group, baseline eosinophil level, optimized OCS dose at baseline, region as covariates. Missing data was imputed using a pattern mixture model by multiple imputation approach.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "A hierarchical testing procedure was used to control the overall type I error. Testing was then performed sequentially in order the outcome measure are reported and continued when previous outcome measure was statistically significant at two-sided 0.05. Only the primary and the first 4 secondary outcome measures were included in the procedure.", "pValue": "< 0.0001", "pValueComment": "Threshold for significance at two-sided 0.05 level.", "statisticalMethod": "ANCOVA", "paramType": "Least Square (LS) Mean Difference", "paramValue": "28.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "15.81", "ciUpperLimit": "40.67", "estimateComment": "LS mean difference represents reduction difference i.e. dupilumab - placebo."}]}, {"type": "PRIMARY", "title": "Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \\[mg/day\\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.", "populationDescription": "Analysis population included ITT patients with available data.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage reduction from baseline", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50.0", "lowerLimit": "0", "upperLimit": "100.0"}, {"groupId": "OG001", "value": "100.0", "lowerLimit": "62.5", "upperLimit": "100.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.3"}, {"groupId": "OG001", "value": "79.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The outcome measure was analyzed using a logistic regression model. The model included the binary status of whether or not a participant achieved the 50% OCS dose reduction criterion as the response variable, and treatment groups, optimized OCS dose at baseline, regions, and baseline eosinophil level subgroups as covariates. Missing data was imputed by using a pattern mixture model by multiple imputation approach.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing was performed according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant).", "pValue": "< 0.0001", "pValueComment": "Threshold for significance at 0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "3.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.06", "ciUpperLimit": "7.67", "estimateComment": "Dupilumab 300 mg q2w v Placebo q2w"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the reduction of OCS dose to \\<5 mg/day was achieved at Week 24.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "37.4"}, {"groupId": "OG001", "value": "71.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The outcome measure was analyzed using a logistic regression model. The model included the binary status of whether or not a participant achieved a reduction of OCS dose to \\<5 mg/day at Week 24 as the response variable, treatment groups, optimized OCS dose at baseline, regions, and baseline eosinophil level subgroups as covariates. Missing data was imputed by using a pattern mixture model by multiple imputation approach.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing was performed according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant).", "pValue": "< 0.0001", "pValueComment": "Threshold for significance at 0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "4.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.39", "ciUpperLimit": "8.39", "estimateComment": "Dupilumab 300 mg q2w v Placebo q2w"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control", "description": "For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.9"}, {"groupId": "OG001", "value": "52.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The outcome was analyzed using a logistic regression model. The model included binary status of whether or not a participant achieved their maximum possible reduction of OCS dose per protocol at Week 24 as the response variable, treatment groups, optimized OCS dose at baseline, regions, and baseline eosinophil level subgroups as covariates. Missing data was imputed by using a pattern mixture model by multiple imputation approach.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing was performed according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant).", "pValue": "0.0024", "pValueComment": "Threshold for significance at 0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.57", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.4", "ciUpperLimit": "4.73", "estimateComment": "Dupilumab 300 mg q2w v Placebo q2w"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.", "populationDescription": "Analysis was performed on ITT population with baseline OCS dose less than or equal to 30 mg/day.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.2"}, {"groupId": "OG001", "value": "52.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The outcome measure was analyzed using a logistic regression model. The model included the binary status of whether or not a participant no longer required OCS at Week 24 as the response variable, and treatment groups, optimized OCS dose at baseline, regions, and baseline eosinophil level subgroups as covariates. Missing data was imputed using a pattern mixture model by multiple imputation approach.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing was performed according to the hierarchical testing procedure (continued only if previous endpoints were statistically significant).", "pValue": "0.0015", "pValueComment": "Threshold for significance at 0.05.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.47", "ciUpperLimit": "5.1", "estimateComment": "Dupilumab 300 mg q2w v Placebo q2w"}]}, {"type": "SECONDARY", "title": "Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control", "description": "Absolute reduction was calculated by subtracting Week 24 value from baseline value.", "populationDescription": "Analysis was performed on ITT population but not included in the hierarchical testing procedure. Here, \"number analyzed\"= participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/day", "timeFrame": "Baseline and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.75", "spread": "6.31"}, {"groupId": "OG001", "value": "10.75", "spread": "5.90"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "101"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.32", "spread": "6.75"}, {"groupId": "OG001", "value": "3.13", "spread": "5.44"}]}]}, {"title": "Absolute reduction at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "101"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.45", "spread": "6.80"}, {"groupId": "OG001", "value": "7.66", "spread": "6.10"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period", "description": "A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \\>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.597", "lowerLimit": "1.248", "upperLimit": "2.043"}, {"groupId": "OG001", "value": "0.649", "lowerLimit": "0.442", "upperLimit": "0.955"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. Here, \"number analyzed\"= participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.61"}, {"groupId": "OG001", "value": "1.53", "spread": "0.53"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "99"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.68", "spread": "0.61"}, {"groupId": "OG001", "value": "1.82", "spread": "0.63"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "99"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.50"}, {"groupId": "OG001", "value": "0.29", "spread": "0.43"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.65"}, {"groupId": "OG001", "value": "1.84", "spread": "0.60"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.51"}, {"groupId": "OG001", "value": "0.29", "spread": "0.46"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24", "description": "The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "populationDescription": "Analysis was performed on ITT population. Here, number analyzed = participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "95"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "0.67"}, {"groupId": "OG001", "value": "-0.49", "spread": "0.86"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "93"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "0.81"}, {"groupId": "OG001", "value": "-0.61", "spread": "1.01"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "96"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "1.13"}, {"groupId": "OG001", "value": "-0.68", "spread": "1.06"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "96"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.54", "spread": "1.17"}, {"groupId": "OG001", "value": "-0.92", "spread": "1.09"}]}]}, {"title": "Change at Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "95"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "spread": "1.05"}, {"groupId": "OG001", "value": "-0.87", "spread": "1.18"}]}]}, {"title": "Change at Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.53", "spread": "1.09"}, {"groupId": "OG001", "value": "-0.83", "spread": "1.19"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "96"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "spread": "1.19"}, {"groupId": "OG001", "value": "-0.94", "spread": "1.22"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24", "description": "AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "populationDescription": "Analysis was performed on ITT population. Here, number analyzed = participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.56", "spread": "1.08"}, {"groupId": "OG001", "value": "0.78", "spread": "1.09"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.56", "spread": "0.97"}, {"groupId": "OG001", "value": "0.94", "spread": "1.17"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24", "description": "EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).", "populationDescription": "Analysis was performed on ITT population. Here, number analyzed = participants with available data for specified categories", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Single Index: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.20"}, {"groupId": "OG001", "value": "0.03", "spread": "0.17"}]}]}, {"title": "Single Index: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.18"}, {"groupId": "OG001", "value": "0.05", "spread": "0.18"}]}]}, {"title": "VAS Score: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.99", "spread": "16.85"}, {"groupId": "OG001", "value": "9.34", "spread": "18.20"}]}]}, {"title": "VAS Score: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.16", "spread": "16.74"}, {"groupId": "OG001", "value": "11.06", "spread": "17.60"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24", "description": "The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.", "populationDescription": "Analysis was performed on ITT population. Here, number analyzed = participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "spread": "5.50"}, {"groupId": "OG001", "value": "-2.13", "spread": "5.32"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.99", "spread": "5.36"}, {"groupId": "OG001", "value": "-2.53", "spread": "5.98"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24", "description": "The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.", "populationDescription": "Analysis was performed on ITT population with bilateral nasal polyposis/chronic rhinosinusitis. Here, number analyzed = participants with available data for specified categories.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, Week 12 and Week 24", "groups": [{"id": "OG000", "title": "Placebo q2w", "description": "2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}, {"id": "OG001", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "31"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "29"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.79", "spread": "21.34"}, {"groupId": "OG001", "value": "-12.45", "spread": "17.10"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.46", "spread": "19.11"}, {"groupId": "OG001", "value": "-14.56", "spread": "15.89"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.", "description": "Reported AEs were treatment emergent AEs developed/worsened occurred during 'treatment-emergent period' (from first dose of study drug injection until 98 days after last dose of drug) or entry in the LTS12551 study (NCT02134028). Analysis was performed on safety population which included all participants who actually received at least 1 dose or part of a dose of the IMP and analyzed according to the treatment that participants actually received.", "eventGroups": [{"id": "EG000", "title": "Placebo q2w", "description": "Participants who received Placebo (for Dupilumab) in combination with OCS and stable ICS (mean exposure of 24 weeks).", "deathsNumAffected": 0, "deathsNumAtRisk": 107, "seriousNumAffected": 6, "seriousNumAtRisk": 107, "otherNumAffected": 30, "otherNumAtRisk": 107}, {"id": "EG001", "title": "Dupilumab 300mg q2w", "description": "Participants who received Dupilumab 300 mg q2w in combination with OCS and stable ICS (mean exposure of 24 weeks).", "deathsNumAffected": 0, "deathsNumAtRisk": 103, "seriousNumAffected": 9, "seriousNumAtRisk": 103, "otherNumAffected": 29, "otherNumAtRisk": 103}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Gastrointestinal stromal tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Eosinophilia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 103}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 103}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Chylothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Pulmonary mass", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Acetabulum fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Foreign body aspiration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 103}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 103}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 103}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 103}]}, {"term": "Eosinophil count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 107}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 103}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-US@sanofi.com", "phone": "800-633-1610", "phoneExt": "1#"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-01-25", "uploadDate": "2018-07-27T18:50", "filename": "Prot_000.pdf", "size": 4598698}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-05-18", "uploadDate": "2018-07-27T18:51", "filename": "SAP_001.pdf", "size": 2436461}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000011241", "term": "Prednisone"}, {"id": "D000011239", "term": "Prednisolone"}, {"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018931", "term": "Antineoplastic Agents, Hormonal"}, {"id": "D000000970", "term": "Antineoplastic Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11749", "name": "Methylprednisolone", "relevance": "LOW"}, {"id": "M1833", "name": "Methylprednisolone Acetate", "relevance": "LOW"}, {"id": "M11750", "name": "Methylprednisolone Hemisuccinate", "relevance": "LOW"}, {"id": "M14120", "name": "Prednisolone", "asFound": "Direct", "relevance": "HIGH"}, {"id": "M229449", "name": "Prednisolone acetate", "relevance": "LOW"}, {"id": "M211887", "name": "Prednisolone hemisuccinate", "relevance": "LOW"}, {"id": "M248881", "name": "Prednisolone phosphate", "relevance": "LOW"}, {"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M14121", "name": "Prednisone", "asFound": "Min", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20966", "name": "Antineoplastic Agents, Hormonal", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "NeuroAg", "name": "Neuroprotective Agents"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}]}}, "hasResults": true}